— Investing in innovative Life Sciences —
Beyond science: the realities that determine value in IP-driven ventures
The field: David vs. Goliath, and who funds the moon mission
Three counterintuitive facts for pioneers
The investor's lens, and what it sharpens
From idea to monetization: deals, value and realization
Readiness: know your stage before you move
Innovative Life Sciences: much more than drug and device!
Innovative Life Sciences encompasses companies advancing biological and medical sciences across human health, agriculture, and the environment. Innovation in this field relies heavily on intellectual property—especially patents—which secure competitive advantage, attract investment, and enable effective technology transfer.
Our key areas of intervention include:
Drug Development
R&D and commercialization of medical drugs from biologics, small molecules, vaccines, gene therapies, and more, designed to prevent, treat, or cure diseases.
Medical Device
Implantable and non-invasive devices as well as patient-facing wearables for diagnosis, treatment, and monitoring.
Diagnostic
Technologies that detect, monitor, and stratify diseases to guide clinical decision and improving outcomes. Used across human and animal health, food safety, and environmental testing.
Innovative Supply Industry
Technologies that power R&D and manufacturing formulation, from bioreactors and bioprocessing to lab automation, sterile packaging, quality and control.
Biotechnology (non drug)
Bio-based innovation beyond therapeutics, including fermentation-derived products, engineered materials, and gene-edited solutions for food, agriculture, energy and cosmetic industries.
Digital Health & Virtual R&D
AI and intuitive digital tools now drive faster drug discovery, smarter trials, and more personalized patient care through better access, monitoring, and decision-making.
Innovative Life Sciences reality: ambitious aims, extra-demanding ground.
Innovative Life Sciences drive progress in medicine and public health, but they operate on complex, highly regulated terrain. It is characterized by extensive research and development (R&D) in cutting-edge, technical domains, often accompanied by significant regulatory considerations. Breakthroughs require time, significant capital, deep expertise, and sustained focus long before revenue emerges. A high growth / high risk challenge.
Life Sciences is shaped like David vs. Goliath.
The field is quite oligopolistic at the top with a few dominant players per business area, generating recurring revenues from billion-dollar products fortified by patent protection. Capital markets reward this scale of steady growth, predictable earnings.
Yet innovation thrives under opposite conditions: scarcity of resources, pressure of time, diversity of approaches. Creativity flourishes in the hands of a different breed: founders, teams, and investors wired for uncertainty.
And so the giants turn to the nimble—seeking breakthroughs born in ventures operating at log-scale smaller size, fuelled by conviction and risk capital.
Innovation pioneers, makers and funders : who’s in for the moon mission?
Tackling innovative Life Sciences is a moon mission. Drug development can be a Mars mission.
It needs financing that is big, ingenious, and costly: the cost-of-capital far exceeds the classic cost-of-debt, reflecting uncertain timelines and the risk of total loss.
Very diverse investors come in: entrepreneurs, industrial players, pure financial players, even philanthropic money, with horizons from short to long term. A family office-led, VC-led or mixed cap table makes for a very different venture experience and often reflects profoundly different innovative approaches. Every capitalization table is unique.
Moon (and Mars!) mission participants live the tension between driving science vs. driving cash return. By journey's end, pathfinders have mastered finance, negotiation, governance and Market-to-Bench thinking. They emerge as adamantium-grade leaders!
Are governments part of the mission? They can be supportive but it is not the norm. Institutions in general, from governments to large industry players and capital markets, run on so different pace and logic that pioneers forge ahead, more alone than wished, to bring health innovation to life.
What´s more supportive is that the playground is global: talent, R&D, financing and markets span countries. What enables reach also bring exposure. To capitalize on the opportunity, stakeholders need more than vision: strong execution and readiness.
From the moon, the view is clear, but getting there demands everything.
Moon mission today
Better tomorrow
This is the drive that defines innovative Life Sciences pioneering—at least where we work. In practice, it takes many forms:
- First-in-class, new standard, and paradigm shifting innovation
- A handful of believers can move worlds
- Personal achievement
- Financial reward
- The ability to do it again, capitalizing on prior success and stepping into stronger roles.
3 counterintuitive facts for Life Sciences´pioneers
- Capital is abundant. Life Sciences holds plenty of it, ready for innovation. The scarce part is the match.
- A signature is a decision, not always a belief. Investors and industrials sign for their own reasons: portfolio, pipeline, return.
- The biggest headache comes after the deal. Keeping alignment across time and events is herculean.
Anticipate the (non-pioneer) investor’s lens
Every investor comes with a rationale: market focus, asset characteristics, team readiness, risk/reward profile and time horizon. It keeps evolving, shaped by past performance, portfolio mix, emerging trends and fears. Not all investors have a pioneer mindset.
Innovators think forward, iterate freely and embrace scientific honesty, acknowledging flaws while pursuing near-utopian ideals. Non-pioneer investors retro-plan. For them, an investment is a calculated bet, with limited tolerance for iteration and doubt. Resilience to pivots and setbacks tightens as monetization nears, and expectations and communication shift from entry to the final stages, just before a deal, IPO or commercialization.
The biggest breakthroughs in Life Sciences come from keeping the patient in mind, in a creative, scientific and often humanistic process, so the investor's lens can feel terribly constraining. Yet it often sharpens the work. Tenfold. Constraints push a team to focus on what its scientific minds will not compromise on. That is gold for patients, and often the holy grail of the innovation. The unpleasant, intense extraction process brings it into view.
When uncertainty peaks, some insiders may dwell on fear or hope. These market signals are visible and read. Alignment is valued while embedded conflict signals capital to pass or severely discount.
From first idea to market, a venture may go through half a dozen to a dozen financing events. Each one puts the past and the future back into question, and tests vision, execution and resilience. This turns pioneers into pathfinders.
Life Sciences pioneers are fiercely passionate, and their knowledge runs deep. Investors read it through another lens, and they are the partners who make the crossing possible.
Invention becomes innovation when real people adopt it. Every venture faces this pathfinder challenge, and it is crossed together with capital.
From idea to monetization in innovative Life Sciences
In Life Sciences, innovation in almost always changes hands: from academia to ventures, to global players. These transitions are anything but trivial, each is a project of its own. Innovation can be licensed or acquired, through asset or equity deals, and each structure fits a specific context rather than an ideal.
From deal to return on investment, much more than a handshake is needed: careful planning beforehand and rigorous monitoring afterward. Yet the market is built for the next quarter, and it delivers what is enough to pass it. It does not support value AND its realization together. Innovative ventures need much more. Working on both is an internal discipline that pays off only at the end. Pioneers carry value AND realization thinking from the inside, with the few players who can articulate alpha and beta maximization with them.
Listed Life Sciences companies live a particular life. Capital markets are built around sales-driven businesses with recurring revenues, while Life Sciences ventures are event-driven. Quarterly expectations bring planning, reporting and governance discipline, and they strain long-term vision, especially when the cash runway is around or less than 12 months. Going concern comes under greater scrutiny, which pushes financial robustness ahead of pure pioneer moves and bets.
Experience, and a crowded life sciences innovation graveyard, show that the best science needs more than science to cross the finish line. Breakthrough ideas stall on financing gaps, cap-table or investor/management mismatches, IP weaknesses, unsuitable deal structures, insufficient post-deal monitoring.
Science is only one of the risks.
Reading readiness: where a venture stands vs. where its next partner expects it to be
Every pioneer needs a map of where they stand.
Innovative Life Sciences is a well-established field, with clear milestones across R&D stages and corporate maturity, especially in funding and deal-making.
Investors, industrial players, experts and veterans each apply their own criteria to judge an asset's readiness. Those criteria drive go/no-go decisions and shape where to push, how to pressure-test a venture, challenge a narrative or use bargaining power.
At every R&D stage, readiness means closing the gap between where a nimble venture stands today and what strategic or financial players expect from a plug-and-play opportunity. Team, asset story and equity story move together, and cohesion wins the game.
Time To Act ? Time To Train ?
